Taken together with the promising results in Alzheimer's patients (Gejl et al., 2016), and the prevalence of metabolic disturbances in patients with MS, these data warrant further studies into GLP-1-based therapy as a future contributor to the MS treatment paradigm. Here, GCG is linked to myeloid sarcoma.